Jakob Dupont - 10 Feb 2022 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role: EVP, Head of R&D
Signature: /s/ David Tucker, Attorney-in-Fact for Jakob Dupont
Issuer symbol: ATRA
Transactions as of: 10 Feb 2022
Net transactions value: -$32,100
Form type: 4
Filing time: 14 Feb 2022, 16:42:34 UTC
Previous filing: 05 Jan 2022
Next filing: 03 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATRA	Common Stock	Options Exercise	$47,900	+5,000	+5.5%	$9.58	95,594	10 Feb 2022	Direct	F1
transaction	ATRA	Common Stock	Sale	$80,000	-5,000	-5.2%	$16.00^*	90,594	10 Feb 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATRA	Employee Stock Option (Right to Buy)	Options Exercise	$0	-5,000	-1.9%	$0.000000	257,500	10 Feb 2022	Common Stock	5,000	$9.58	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021.
F2	25% of the shares subject to the option vested on May 14, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service.